{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:13:22Z","timestamp":1772133202992,"version":"3.50.1"},"reference-count":41,"publisher":"IMR Press","issue":"3","license":[{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Integr. Neurosci."],"abstract":"<jats:p>Autonomic involvement, including cardiac denervation, may precede the motor symptoms of Parkinson\u2019s disease by several years. L-3,4-dihydroxy-6-[18F] fluoro-phenylalanine is a positron emitter and a true analog of L-dopa, used in clinical practice to assess striatal dopaminergic integrity. The present study aimed to assess the feasibility of evaluating cardiac sympathetic denervation in Parkinson\u2019s disease patients using L-3,4-dihydroxy-6-[18F] fluoro-phenylalanine positron emission tomography\/computed tomography. Patients referred for an L-3,4-dihydroxy-6-[18F] fluoro-phenylalanine positron emission tomography\/computed-tomography between July 2015 and May 2017 to evaluate striatal presynaptic dopaminergic integrity underwent a heart positron emission tomography scan following a brain positron emission tomography scan. L-3,4-dihydroxy-6-[18F] fluoro-phenylalanine uptake in the left ventricle was quantified using CarimasT\u2062M software and compared between patients with and without Parkinson\u2019s disease. The area under the receiver operating characteristic curve was used to evaluate the ability of the left ventricular mean standardized uptake value to discriminate between patients with Parkinson\u2019s disease and those with other extrapyramidal syndromes. Seventy-six patients were included, of whom 52 were diagnosed with Parkinson\u2019s disease. The mean L-3,4-dihydroxy-6-[18F] fluoro-phenylalanine left ventricular mean standardized uptake value was lower in the Parkinson\u2019s disease patients compared to the non- Parkinson\u2019s disease patients (1.08 \u00b1 0.21 vs. 1.24 \u00b1 0.32, P = 0.015). The left ventricular mean standardized uptake value was able to discriminate between Parkinson\u2019s disease and non- Parkinson\u2019s disease patients (the area under the receiver operating characteristic curve = 0.641, P = 0.049). In conclusion, quantification of cardiac L-3,4-dihydroxy-6-[18F] fluoro-phenylalanine uptake may be able to differentiate between patients with and without Parkinson\u2019s disease. Validation of this finding in more substantial, prospective trials are warranted.<\/jats:p>","DOI":"10.31083\/j.jin.2020.03.196","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T01:38:25Z","timestamp":1602639505000},"source":"Crossref","is-referenced-by-count":13,"title":["[18F] FDOPA PET may confirm the clinical diagnosis of Parkinson's disease by imaging the nigro-striatal pathway and the sympathetic cardiac innervation: Proof-of-concept study"],"prefix":"10.31083","volume":"19","author":[{"given":"Jonathan","family":"Kuten","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Tel-Aviv Sourasky Medical Center, Tel-Aviv, 6423906, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adi","family":"Linevitz","sequence":"first","affiliation":[{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, 6997801, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hedva","family":"Lerman","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Tel-Aviv Sourasky Medical Center, Tel-Aviv, 6423906, Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, 6997801, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanette","family":"Freedman","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Tel-Aviv Sourasky Medical Center, Tel-Aviv, 6423906, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meir","family":"Kestenbaum","sequence":"first","affiliation":[{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, 6997801, Israel"},{"name":"Movement Disorders Unit, Neurological Institute, Tel-Aviv Sourasky Medical Center, Tel-Aviv, 6423906, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Shiner","sequence":"first","affiliation":[{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, 6997801, Israel"},{"name":"Movement Disorders Unit, Neurological Institute, Tel-Aviv Sourasky Medical Center, Tel-Aviv, 6423906, Israel"},{"name":"Sagol School of Neurosciences, Tel-Aviv University, Tel-Aviv, 6997801, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nir","family":"Giladi","sequence":"first","affiliation":[{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, 6997801, Israel"},{"name":"Movement Disorders Unit, Neurological Institute, Tel-Aviv Sourasky Medical Center, Tel-Aviv, 6423906, Israel"},{"name":"Sagol School of Neurosciences, Tel-Aviv University, Tel-Aviv, 6997801, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Einat","family":"Even-Sapir","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Tel-Aviv Sourasky Medical Center, Tel-Aviv, 6423906, Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, 6997801, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","published-online":{"date-parts":[[2020,9,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Balogova, S., Talbot, J., Nataf, V., Michaud, L., Huchet, V., Kerrou, K. and Montravers, F. (2013) 18F-Fluorodihydroxyphenylalanine vs. other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. European Journal of Nuclear Medicine and Molecular Imaging 40, 943-966.","DOI":"10.1007\/s00259-013-2342-x"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Braak, H., Ghebremedhin, E., R\u00fcb, U., Bratzke, H. and Del Tredici, K. (2004) Stages in the development of Parkinson\u2019s disease-related pathology. Cell and Tissue Research 318, 121-134.","DOI":"10.1007\/s00441-004-0956-9"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Braune, S. (2001) The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clinical Autonomic Research 11, 351-355.","DOI":"10.1007\/BF02292766"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Dhawan, V., Ma, Y., Pillai, V., Spetsieris, P., Chaly, T. and Eidelberg, D. (2002) Comparative analysis of striatal FDOPA uptake in Parkinson\u2019s disease: ratio method versus graphical approach. Journal of Nuclear Medicine 43, 1324-1230.","DOI":"10.1016\/B978-012636651-8\/50045-3"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Druschky, A., Hilz, M. J., Platsch, G., Radespiel-Tr\u00f6ger, M., Druschky, K., Kuwert, T. and Neund\u00f6rfer, B. (2000) Differentiation of Parkinson\u2019s Disease and multiple system atrophy in early disease stages by means of I-123-MIBG\u2013SPECT. Journal of the Neurological Sciences 175, 3-12.","DOI":"10.1016\/S0022-510X(00)00279-3"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Eshuis, S. A., Maguire, R. P., Leenders, K. L., Jonkman, S. and Jager, P. L. (2006) Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson\u2019s Disease. European Journal of Nuclear Medicine and Molecular Imaging 33, 200-209.","DOI":"10.1007\/s00259-005-1904-y"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Garnett, E. S., Firnau, G. and Nahmias, C. (1983) Dopamine visualized in the basal ganglia of living man. Nature 305, 137-138.","DOI":"10.1038\/305137a0"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Goldstein, D. S. (2013) Sympathetic neuroimaging. Handbook of Clinical Neurology 117, 365-370.","DOI":"10.1016\/B978-0-444-53491-0.00029-8"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Goldstein, D. S. and Holmes, C. (1997) Metabolic fate of the sympathoneural imaging agent 6-[18F] fluorodopamine in humans. Clinical and Experimental Hypertension 19, 155-161.","DOI":"10.3109\/10641969709080812"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Goldstein, D. S., Holmes, C., Bentho, O., Sato, T., Moak, J., Sharabi, Y., Imrich, R., Conant, S. and Eldadah, B. A. (2008) Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism and Related Disorders 14, 600-607.","DOI":"10.1016\/j.parkreldis.2008.01.010"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Goldstein, D. S., Holmes, C., Frank, S. M., Dendi, R., Cannon, R. O., Sharabi, Y., Esler, M. D. and Eisenhofer, G. (2002) Cardiac sympathetic dysautonomia in chronic orthostatic intolerance syndromes. Circulation 106, 2358-2365.","DOI":"10.1161\/01.CIR.0000036015.54619.B6"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Goldstein, D. S., Holmes, C., Lopez, G. J., Wu, T. and Sharabi, Y. (2018) Cardiac sympathetic denervation predicts PD in at-risk individuals. Parkinsonism and Related Disorders 52, 90-93.","DOI":"10.1016\/j.parkreldis.2017.10.003"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Goldstein, D. S., Kopin, I. J., Sharabi, Y. and Holmes, C. (2015) Plasma biomarkers of decreased vesicular storage distinguish Parkinson disease with orthostatic hypotension from the parkinsonian form of multiple system atrophy. Clinical Autonomic Research 25, 61-67.","DOI":"10.1007\/s10286-015-0268-z"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Goldstein, D. S., Sewell, L. and Holmes, C. (2010) Association of anosmia with autonomic failure in Parkinson Disease. Neurology 74, 245-251.","DOI":"10.1212\/WNL.0b013e3181ca014c"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Goldstein, D. S., Sewell, L. and Sharabi, Y. (2011) Autonomic dysfunction in PD: a window to early detection? Journal of the Neurological Sciences 310, 118-122.","DOI":"10.1016\/j.jns.2011.04.011"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Goldstein, D. S., Sharabi, Y., Karp, B. I., Bentho, O., Saleem, A., Pacak, K. and Eisenhofer, G. (2007) Cardiac sympathetic denervation preceding motor signs in Parkinson disease. Clinical Autonomic Research 17, 118-121.","DOI":"10.1007\/s10286-007-0396-1"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Goldstein, D. S., Sullivan, P., Holmes, C., Miller, G. W., Sharabi, Y. and Kopin, I. J. (2014) A vesicular sequestration to oxidative deamination shift in myocardial sympathetic nerves in Parkinson\u2019s Disease. Journal of Neurochemistry 131, 219-228.","DOI":"10.1111\/jnc.12766"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Hughes, A. J., Daniel, S. E., Kilford, L. and Lees, A. J. (1992) Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s Disease: a clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery & Psychiatry 55, 181-184.","DOI":"10.1136\/jnnp.55.3.181"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Iwasa, K., Nakajima, K., Yoshikawa, H., Tada, A., Taki, J. and Takamori, M. (1998) Decreased myocardial123I-MIBG uptake in Parkinson\u2019s Disease. Acta Neurologica Scandinavica 97, 303-306.","DOI":"10.1111\/j.1600-0404.1998.tb05957.x"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Jacobson, A. F., Senior, R., Cerqueira, M. D., Wong, N. D., Thomas, G. S., Lopez, V. A., Agostini, D., Weiland, F., Chandna, H. and Narula, J. (2010) Myocardial Iodine-123 Meta-Iodobenzylguanidine imaging and cardiac events in heart failure. Journal of the American College of Cardiology 55, 2212-2221.","DOI":"10.1016\/j.jacc.2010.01.014"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Kim, J. S., Park, H. E., Park, I. S., Oh, Y. S., Ryu, D. W., Song, I. U., Jung, Y. A., Yoo, I. R., Choi, H. S., Lee, P. H. and Lee, K. S. (2017) Normal \u2018heart\u2019 in Parkinson\u2019s Disease: is this a distinct clinical phenotype? European Journal of Neurology 24, 349-356.","DOI":"10.1111\/ene.13206"},{"key":"ref22","unstructured":"Koller, W. C. (1992) When does Parkinson\u2019s Disease begin? Neurology 42, 27-28."},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Li, S., Dendi, R., Holmes, C. and Goldstein, D. S. (2002) Progressive loss of cardiac sympathetic innervation in Parkinson\u2019s Disease. Annals of Neurology 52, 220-223.","DOI":"10.1002\/ana.10236"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Lovenberg, W., Weissbach, H. and Udenfriend, S. (1962) Aromatic L-amino acid decarboxylase. The Journal of Biological Chemistry 237, 89-93.","DOI":"10.1016\/S0021-9258(18)81366-7"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Manabe, Y., Inui, Y., Toyama, H. and Kosaka, K. (2017) 123I-metaiodobenzylguanidine myocardial scintigraphy with early images alone is useful for the differential diagnosis of dementia with Lewy bodies. Psychiatry Research: Neuroimaging 261, 75-79.","DOI":"10.1016\/j.pscychresns.2016.12.011"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Merola, A., Sawyer, R. P., Artusi, C. A., Suri, R., Berndt, Z., Lopez-Castellanos, J. R., Vaughan, J., Vizcarra, J. A., Romagnolo, A. and Espay, A. J. (2018) Orthostatic hypotension in Parkinson Disease: impact on health care utilization. Parkinsonism and Related Disorders 47, 45-49.","DOI":"10.1016\/j.parkreldis.2017.11.344"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Miyamoto, T., Miyamoto, M., Inoue, Y., Usui, Y., Suzuki, K. and Hirata, K. (2006) Reduced cardiac 123I-MIBG scintigraphy in idiopathic REM sleep behavior disorder. Neurology 67, 2236-2238.","DOI":"10.1212\/01.wnl.0000249313.25627.2e"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Nanni, C., Fanti, S. and Rubello, D. (2007) 18F-DOPA PET and PET\/CT. Journal of Nuclear Medicine 48, 1577-1579.","DOI":"10.2967\/jnumed.107.041947"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Nesterov, S. V., Han, C., M\u00e4ki, M., Kajander, S., Naum, A. G., Helenius, H., Lisinen, I., Ukkonen, H., Pietil\u00e4, M., Joutsiniemi, E. and Knuuti, J. (2009) Myocardial perfusion quantitation with 15O-labelled water PET: high reproducibility of the new cardiac analysis software (Carimas\u2122). European Journal of Nuclear Medicine and Molecular Imaging 36, 1594-1602.","DOI":"10.1007\/s00259-009-1143-8"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Neurauter, G., Schrocksnadel, K., Scholl-Burgi, S., Sperner-Unterweger, B., Schubert, C., Ledochowski, M. and Fuchs, D. (2008) Chronic immune stimulation correlates with reduced phenylalanine turnover. Current Drug Metabolism 9, 622-627.","DOI":"10.2174\/138920008785821738"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Oka, H., Mochio, S., Onouchi, K., Morita, M., Yoshioka, M. and Inoue, K. (2006) Cardiovascular dysautonomia in de novo Parkinson\u2019s Disease. Journal of the Neurological Sciences 241, 59-65.","DOI":"10.1016\/j.jns.2005.10.014"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Oka, H., Toyoda, C., Yogo, M. and Mochio, S. (2011) Cardiovascular dysautonomia in de novo Parkinson\u2019s Disease without orthostatic hypotension. European Journal of Neurology 18, 286-292.","DOI":"10.1111\/j.1468-1331.2010.03135.x"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Orimo, S., Amino, T., Itoh, Y., Takahashi, A., Kojo, T., Uchihara, T., Tsuchiya, K., Mori, F., Wakabayashi, K. and Takahashi, H. (2005) Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathologica 109, 583-588.","DOI":"10.1007\/s00401-005-0995-7"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Orimo, S. (2002) Sympathetic cardiac denervation in Parkinson\u2019s Disease and pure autonomic failure but not in multiple system atrophy. Journal of Neurology, Neurosurgery and Psychiatry 73, 776-776.","DOI":"10.1136\/jnnp.73.6.776"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Orimo, S., Ozawa, E., Oka, T., Nakade, S., Tsuchiya, K., Yoshimoto, M., Wakabayashi, K. and Takahashi, H. (2001) Different histopathology accounting for a decrease in myocardial MIBG uptake in PD and MSA. Neurology 57, 1140-1141.","DOI":"10.1212\/WNL.57.6.1140"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Orimo, S., Uchihara, T., Nakamura, A., Mori, F., Kakita, A., Wakabayashi, K. and Takahashi, H. (2008) Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson\u2019s Disease. Brain: A Journal of Neurology 131, 642-650.","DOI":"10.1093\/brain\/awm302"},{"key":"ref37","unstructured":"Raffel, D. M., Koeppe, R. A., Little, R., Wang, C., Liu, S., Junck, L., Heumann, M. and Gilman, S. (2006) PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes. Journal of Nuclear Medicine 47, 1769-1777."},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Sudmeyer, M., Antke, C., Zizek, T., Beu, M., Nikolaus, S., Wojtecki, L., Schnitzler, A. and Muller, H. (2011) Diagnostic accuracy of combined FP-CIT, IBZM, and MIBG scintigraphy in the differential diagnosis of degenerative Parkinsonism: a multidimensional statistical approach. Journal of Nuclear Medicine 52, 733-740.","DOI":"10.2967\/jnumed.110.086959"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Uyama, N., Otsuka, H., Shinya, T., Otomi, Y., Harada, M., Sako, W., Izumi, Y., Kaji, R., Watanabe, Y., Takashi, S. and Kunikane, Y. (2017) The utility of the combination of a SPECT study with [123I]-FP-CIT of dopamine transporters and [123I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes. Nuclear Medicine Communications 38, 487-492.","DOI":"10.1097\/MNM.0000000000000674"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Velseboer, D. C., de Haan, R. J., Wieling, W., Goldstein, D. S. and de Bie, R. M. A. (2011) Prevalence of orthostatic hypotension in Parkinson\u2019s disease: a systematic review and meta-analysis. Parkinsonism & Related Disorders 17, 724-729.","DOI":"10.1016\/j.parkreldis.2011.04.016"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Yoshii, F., Ryo, M., Baba, Y., Koide, T. and Hashimoto, J. (2017) Combined use of dopamine transporter imaging (DAT-SPECT) and 123 I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy for diagnosing Parkinson\u2019s Disease. Journal of the Neurological Sciences 375, 80-85.","DOI":"10.1016\/j.jns.2017.01.042"}],"container-title":["Journal of Integrative Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/JIN\/19\/3\/10.31083\/j.jin.2020.03.196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T08:02:22Z","timestamp":1747641742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/JIN\/19\/3\/10.31083\/j.jin.2020.03.196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,30]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"alternative-id":["1757-448X-19-3-489"],"URL":"https:\/\/doi.org\/10.31083\/j.jin.2020.03.196","relation":{},"ISSN":["0219-6352","1757-448X"],"issn-type":[{"value":"0219-6352","type":"print"},{"value":"1757-448X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,30]]},"article-number":"489"}}